Self-assembled Transition Metal Coordination Frameworks of ...

C0pper(ll) complexes
Table 4.6. Selected bond lengths (A) and bond angles (°) of compound 13a.
Cu(lA)—N(lA)
Cu(lA)—N(4A)
Cu( l A)—Cl( 1 A)
N(lA)—N(2A)
N(1A)—C(6A)
N(2A)—N(3A)
N(3A)—C(5A)
C(5A)—C(6A)
C(6A)—C(7A)
Cu(2B)—N(lB)
Cu(2B)—N(4B)
Cu(2B)—Cl(2B)
N(lB)—N(2B)
N(1B)—C(6B)
N(2B)—N(3B)
N(3B)—C(5B)
C(5B)—C(6B)
C(6B)—C(7B)
N(lA’)—Cu(lA)—N(lA)
N(lA’)—Cu(lA)—N(4A)
4.4. Anticancer properties
1.996(2)
2.0483(16)
2.6770(13)
1.323(2)
1.351(3)
1.333(2)
1.371(3)
1.410(3)
1.443(3)
1.9876(19)
2.0559(16)
2.6772(14)
1.330(2)
1.365(3)
1.329(2)
1.368(3)
1.416(3)
1.431(3)
180.000(1)
99.96(7)
N(lA)—Cu(lA)—N(4A)
N(4A)—Cu(lA)—N(4A’)
N(lA)—Cu(lA)—Cl(lA’)
N(4A)—Cu(lA)—Cl(lA’)
N(lA’)—Cu(lA)—Cl(lA)
N(lA)—Cu(lA)—Cl(1A)
N(4A)—Cu(lA)—Cl(lA)
N(4A’)—Cu(1A)-—Cl(lA)
Cl(lA’)—Cu(lA)—Cl(lA)
N(lB’)—Cu(2B)—N(lB)
N(lB)—Cu(2B)—N(4B’)
N(lB’)—Cu(2B)—N(4B)
N(lB)—Cu(2B)—N(4B)
N(4B’)—Cu(2B)—N(4B)
N(lB)—Cu(2B)—Cl(2B’)
N(4B)—Cu(2B)—Cl(2B’)
N(lB’)—Cu(2B)—Cl(2B)
N(lB)—Cu(2B)—Cl(2B)
N(4B’)—Cu(2B)—Cl(2B)
N(4B)—Cu(2B)—Cl(2B)
Cl(2B’)—Cu(2B)—Cl(2B)
80.04(7)
180.000(1)
88.56(6)
88.39(6)
88.56(6)
91.44(6)
91 .61(6)
88.39(6)
180.000(1)
180.00(11)
100.07(7)
100.07(7)
79.93(7)
180.000(1)
88.51(6)
88.38(5)
88.51(6)
91.49(6)
88.38(5)
91.62(5)
180.0
Anticancer activity (in vitro) of selected Cu(II) complexes was analyzed by
standard growth inhibitory assays. Mechanism of action is analyzed in MCF-7 cell
lines and is one of the three cell line panel recommended by NCI (National Cancer
Institute) for anticancer drug screening (NCI developmental therapeutic program).
Determination of the Effectiveness of the compounds was achieved by MTT Cell
Proliferation Assay. The procedures are as reported in Chapter 2. The cell survival of
various compounds in different concentration is summarized in Table 4.7.
187